CLC-2 is a voltage-gated chloride channel expressed ubiquitously in mammalian tissue. Studies to define how CLC-2 contributes to normal and pathophysiological brain function have produced controversial results, in part due to the absence of precise pharmacological tools for modulating CLC-2 function. Herein, we describe the development and optimization of a new small-molecule inhibitor of CLC-2, AK-42, that exhibits unprecedented potency and specificity. Computational docking, validated by mutagenesis and kinetic studies, indicates that AK-42 binds to an extracellular vestibule above the channel pore. AK-42 acutely and specifically inhibits CLC-2 currents in CA1 hippocampal pyramidal neurons. Use of AK-42 in an established thalamic-slice model for studying epilepsy suggests a role for CLC-2 in modulating electrical excitability and implicates CLC-2 as a possible anti-epileptic target. These results establish AK-42 as a powerful new tool for investigating CLC-2 physiology in the central nervous system.The CLC-2 channel belongs to the "CLC" family of Cl --selective ion channels and transporters, of which there are nine mammalian homologs 9 . CLC-2 is activated by hyperpolarization of the plasma membrane and is expressed in nearly every tissue-type, including brain, heart, intestines, and lungs 10 . Interest in CLC-2 physiology in the CNS was sparked by CLC-2 knockout mouse phenotypes, which display severe deficiencies, including retinal degeneration/blindness and vacuolization of myelin in brain tissue [11][12][13] . In addition, human patient data suggest a link between CLC-2 malfunction and certain forms of generalized epilepsies [14][15][16][17][18][19][20][21] . Although a causative role for CLC-2 underlying genetic disease remains controversial 22,23 , the available research, together with the widespread expression of CLC-2 in the CNS 10,11,24-28 , motivate further examination of this channel.Understanding CLC-2 physiology has proven difficult in the absence of selective and specific chemical reagents for labeling and modulating the activity of this ion channel. Commercially available Cl --channel inhibitors 29 lack potency, with mid-µM to mM concentrations required to achieve inhibition of Clcurrent 9,30-32 .These molecules also generally lack selectivity against the different types of Clchannels, which strictly limits the usefulness of these compounds for cellular and organismal studies. For the CLC channels, the most potent and selective small-molecule inhibitors are those targeting CLC-Ka, one of two CLC homologs expressed in the kidney [33][34][35][36] . For CLC-2, the only reported small-molecule (non-peptide) inhibitors require application of high concentrations (~1 mM) 9,10,24,37 . CLC-2 is also inhibited by low µM concentrations of the divalent cations, Cd 2+ and Zn 2+ 38,39 ; however, these ions are toxic and lack subtype specificity. A peptide toxin, GaTx2, has been reported to selectively inhibit CLC-2 at concentrations of ~20 pM 40 ; however, current inhibition saturates at ~50% with the applicat...